查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1736504

三价流感疫苗市场－依疫苗类型、年龄层、通路、地区分類的全球市场规模及预测－2020 年

Global Trivalent Flu Vaccine Market Size By Type of Vaccine (Inactivated Influenza Vaccines, Live Attenuated Influenza Vaccines ), By Age Group, By Distribution Channel, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 | 商品交期: 2-3个工作天内

价格
简介目录

三价流感疫苗市场规模及预测

2024 年三价流感疫苗市场规模为 63.6 亿美元，预计到 2032 年将达到 95.9 亿美元，2026 年至 2032 年的复合年增长率为 5.80%。

推动全球三价流感疫苗市场的因素

三价流感疫苗市场的驱动因素可能受到多种因素的影响。这些因素包括：

流感病毒株的流行：疫苗接种需求直接受到流感病毒株（尤其是三价疫苗所预防的病毒株）的流行程度和严重程度的影响。流行病毒株的变化可能导致疫苗成分和需求的改变。

政府建议与法规：流感疫苗产品的市场需求可能受到政府法规和卫生当局建议的显着影响。可以透过公共卫生宣传活动提高流感疫苗接种覆盖率。

医疗基础设施和认知：获得医疗服务以及对流感疫苗接种价值的认知至关重要。改善医疗设施和开展教育活动可以提高疫苗接种覆盖率，从而推动市场扩张。

季节性变化与疫情：流感疫苗接种需求可能会因季节性、偶发性或大流行性流感而增加。 COVID-19 疫情等事件也可能影响流感疫苗的需求和认知度。

技术发展：疫苗生产技术的发展，例如基于细胞和重组疫苗製造，可能会透过提高疫苗有效性、降低生产成本和增加供给能力来影响市场。

人口因素：疫苗需求可能受到年龄分布和流感併发症易感性等因素的影响。老年人、幼儿和长期患病者等高危险群可能会推动需求。

医疗费用和保险覆盖：流感疫苗的费用和可近性受医疗费用和保险覆盖的影响。随着保险覆盖范围和报销标准的扩大，疫苗接种率可能会提高。

竞争格局：生产三价流感疫苗的製药公司之间的竞争可能会影响产品创新、定价和分销管道。

全球化与旅行：随着世界旅行和全球化的增加，流感病毒已在​​世界范围内传播，增加了流感疫苗接种的需求。

限制全球三价流感疫苗市场的因素

多种因素可能对三价流感疫苗市场造成限制和挑战。这些因素包括：

疫苗有效性：三价流感疫苗的有效性可能因疫苗与目前流行的病毒株的相似程度而异。疫苗与常见株之间的差异可能会降低疫苗效力，并削弱大众对疫苗宣传活动的信心。

对疫苗安全性的担忧：对疫苗成分安全性和副作用的担忧可能会使人们犹豫是否接种疫苗。错误讯息会影响人们对疫苗安全性的认知，导致人们产生疫苗犹豫。

医疗服务可近性有限：医疗服务可近性有限，尤其是在农村和服务不足地区，可能会阻碍疫苗的分发和接种。成本、交通途径以及卫生系统缺陷等因素可能会阻碍疫苗的接种。

其他疫苗的竞争：三价疫苗市场可能会受到其他流感疫苗剂型（例如滴鼻剂和四价疫苗）的竞争影响。为了维持市场占有率，製造商需要使其产品差异化，并证明其更安全、更有效。

监管难题：製造商必须承担成本并面临行政管理难题，以遵守有关疫苗接种授权、生产标准和上市后监管的法规。监管程序的延误和不确定性可能会阻碍市场准入和扩张。

全球经济状况：景气衰退或经济低迷可能会影响卫生支出重点，从而导致疫苗接种计画的预算限制，并降低消费者自掏腰包接种疫苗的意愿。

疫苗犹豫：疫苗犹豫会削弱大众对流感疫苗的信心，并因错误讯息、对医疗机构的不信任和文化观念等因素而阻碍市场扩张。

疫苗供应链中断，包括原材料短缺、製造过程中的问题或分销困难，可能导致供不应求或延迟，并影响市场上疫苗的可用性和可及性。

疫情疲劳：儘管人们对疫情带来的风险有了更多的了解，但对流感和疫苗宣传活动的冷漠或疲劳可能会降低接种流感疫苗的紧迫性，尤其是在流感活动较低的时期。

目录

第一章全球三价流感疫苗市场介绍

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章全球三价流感疫苗市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

5. 全球三价流感疫苗市场（依疫苗类型）

  • 概述
  • 灭活流感疫苗（IIV）
  • 减毒活流感疫苗（LAIV）
  • 重组流感疫苗

6. 全球三价流感疫苗市场（依年龄层）

  • 概述
  • 儿童疫苗
  • 成人疫苗
  • 老年人疫苗

7. 全球三价流感疫苗市场（依分销管道）

  • 概述
  • 医院和诊所
  • 药局
  • 公共卫生项目

8. 全球三价流感疫苗市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区
    • 拉丁美洲
    • 中东和非洲

9. 全球三价流感疫苗市场竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第十章 公司简介

  • AstraZeneca
  • Sanofi SA
  • Abbott
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer
  • Johnson & Johnson
  • Serum Institute of India
  • CSL Limited

第十一章 附录

  • 相关调查
简介目录
Product Code: 37130

Trivalent Flu Vaccine Market Size And Forecast

Trivalent Flu Vaccine Market size was valued at USD 6.36 Billion in 2024 and is projected to reach USD 9.59 Billion by 2032, growing at a CAGR of 5.80% from 2026 to 2032.

Global Trivalent Flu Vaccine Market Drivers

The market drivers for the Trivalent Flu Vaccine Market can be influenced by various factors. These may include:

Influenza Strain Prevalence:The demand for the vaccination is directly impacted by the frequency and severity of influenza strains, especially those that are protected by the trivalent vaccine. Variations in vaccine composition and demand can be caused by changes in circulating strains.

Government Recommendations and Regulations:The market demand for flu vaccine products can be greatly impacted by government regulations and recommendations made by health authorities. Uptake rates of the flu vaccination can be increased via public health campaigns.

Healthcare Infrastructure and Awareness:Having access to healthcare services and being aware of the value of getting vaccinated against the flu are essential. Enhanced healthcare facilities and education initiatives can raise immunization rates, which will propel market expansion.

Seasonal changes and Epidemics:Flu vaccination demand may rise in response to seasonal changes in flu outbreaks as well as sporadic epidemics or pandemics. The demand for and awareness of flu vaccinations can also be influenced by events like the COVID-19 pandemic.

Technological Developments:By increasing vaccine efficacy, lowering production costs, and increasing supply capacity, developments in vaccine manufacturing technology, such as cell-based or recombinant vaccine production, can have an impact on the market.

Demographic Factors:The demand for vaccines can be influenced by factors such as age distribution and vulnerability to complications from the flu. Demand may be driven by high-risk demographics like the elderly, small children, and people with long-term medical issues.

Healthcare Costs and Insurance Coverage:The cost and availability of flu shots are influenced by healthcare costs and insurance coverage. Vaccination rates can rise as a result of expanded insurance coverage and reimbursement guidelines.

Competitive Landscape:The rivalry between pharmaceutical firms producing trivalent flu shots can have an impact on product innovation, pricing, and distribution routes.

Globalization and Travel:As a result of increased worldwide travel and globalization, influenza viruses are spreading around the world, increasing the need for flu vaccinations.

Global Trivalent Flu Vaccine Market Restraints

Several factors can act as restraints or challenges for the Trivalent Flu Vaccine Market. These may include:

Vaccine Efficacy: Depending on how closely the vaccine resembles the viral strains that are currently in circulation, the effectiveness of trivalent flu shots can differ. Inconsistencies between the vaccine and common strains might diminish effectiveness and erode public trust in immunization campaigns.

Vaccine Safety Concerns: People may be discouraged from getting vaccinated due to worries about the safety of the vaccine's ingredients or side effects, which could affect the market's uptake. Misinformation can affect people's perceptions of vaccine safety, which can result in vaccine hesitation.

Restricted Access to Healthcare Services: Distribution and administration of vaccines may be hampered by limited access to healthcare services, especially in rural or underserved areas. The uptake of vaccines may be hampered by obstacles like cost, transportation, and deficiencies in the healthcare system.

Competition from Other vaccinations:The market for trivalent vaccinations may be impacted by competition from other flu vaccine formulations, such as nasal spray or quadrivalent vaccines. To retain market share, manufacturers need to set their products apart and show that they are safer or more effective.

Regulatory Difficulties: Manufacturers must incur money and bear administrative difficulties in order to comply with regulations pertaining to vaccination licensing, manufacturing standards, and post-market surveillance. Market entry or expansion may be hampered by regulatory procedural delays or uncertainty.

Global Economic Situation: Recessions and downturns in the economy can have an impact on healthcare spending priorities, which can result in budgetary restrictions for immunization programs and a decline in the willingness of consumers to pay for vaccinations out of pocket.

Vaccine Hesitancy: Vaccine hesitancy can damage public confidence in flu vaccination and impede market expansion. It might be caused by disinformation, mistrust of healthcare authorities, or cultural views.

Disruptions in the vaccine supply chain, such as shortages of raw materials, problems during manufacturing, or difficulties with distribution, can result in shortages or delays in the supply, which can affect the accessibility and availability of the vaccine on the market.

Fatigue from Pandemic Preparedness: Even with heightened knowledge of the hazards posed by pandemics, apathy or fatigue with regard to influenza and vaccine campaigns might lessen the urgency of getting vaccinated against the flu, especially in times of low flu activity.

Global Trivalent Flu Vaccine Market Segmentation Analysis

The Global Trivalent Flu Vaccine Market is Segmented on the basis of Type of Vaccine, Age Group, Distribution Channel, and Geography.

Type of Vaccine:

Inactivated Influenza Vaccines (IIV): These vaccines contain killed influenza viruses and are administered via injection.

Live Attenuated Influenza Vaccines (LAIV): These vaccines contain weakened influenza viruses and are administered via nasal spray.

Recombinant Influenza Vaccines: These vaccines are produced by genetic engineering methods and do not require the use of flu virus.

Age Group:

Pediatric Vaccines: Designed for children, typically aged 6 months to 17 years.

Adult Vaccines: Targeted for individuals aged 18 to 64 years who do not fall into the pediatric or elderly categories.

Elderly Vaccines: Specifically formulated for individuals aged 65 years and above, who are at higher risk of flu-related complications.

Distribution Channel:

Hospitals and Clinics: Vaccines are distributed through healthcare facilities where they are administered by healthcare professionals.

Pharmacies: Vaccines are available for purchase and administration at retail pharmacies.

Public Health Programs: Distribution occurs through government-run vaccination campaigns and public health initiatives.

Geography:

North America: Market conditions and demand in the United States, Canada, and Mexico.

Europe: Analysis of the Trivalent Flu Vaccine Market in European countries.

Asia-Pacific: Focusing on countries like China, India, Japan, South Korea, and others.

Middle East and Africa: Examining market dynamics in the Middle East and African regions.

Latin America: Covering market trends and developments in countries across Latin America.

Key Players

Sanofi Pasteur

GlaxoSmithKline (GSK)

Seqirus

Merck & Co., Inc.

Pfizer Inc.

F. Hoffmann-La Roche Ltd.

CSL Limited

Mylan N.V.

AstraZeneca

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL TRIVALENT FLU VACCINE MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL TRIVALENT FLU VACCINE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL TRIVALENT FLU VACCINE MARKET, BY TYPE OF VACCINE

  • 5.1 Overview
  • 5.2 Inactivated Influenza Vaccines (IIV)
  • 5.3 Live Attenuated Influenza Vaccines (LAIV)
  • 5.4 Recombinant Influenza Vaccines

6 GLOBAL TRIVALENT FLU VACCINE MARKET, BY AGE GROUP

  • 6.1 Overview
  • 6.2 Pediatric Vaccines
  • 6.3 Adult Vaccines
  • 6.4 Elderly Vaccines

7 GLOBAL TRIVALENT FLU VACCINE MARKET, BY DISTRIBUTION CHANNEL

  • 7.1 Overview
  • 7.2 Hospitals and Clinics
  • 7.3 Pharmacies
  • 7.4 Public Health Programs

8 GLOBAL TRIVALENT FLU VACCINE MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East & Africa

9 GLOBAL TRIVALENT FLU VACCINE MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 AstraZeneca
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Sanofi S.A
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Abbott
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 GlaxoSmithKline
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Merck
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Novartis
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Pfizer
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Johnson & Johnson
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Serum Institute of India
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 CSL Limited
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 Appendix

  • 11.1 Related Research